(HealthDay News) — Low-dose aspirin can be used for primary cardiovascular prevention for patients at high cardiovascular risk, without increased bleeding risk, according to a review article published in the July 22 issue of the Journal of the American College of Cardiology.

Sigrun Halvorsen, MD, from Oslo University Hospital Ulleval in Norway, and colleagues reviewed the evidence for and against aspirin use in primary cardiovascular prevention.

Based on the currently available evidence of cardiovascular benefits and potentially increased bleeding risk, the researchers recommend that a pragmatic approach should guide low-dose aspirin use in primary cardiovascular prevention. Aspirin is recommended for patients at high cardiovascular risk (defined as ≥2 major cardiovascular events projected per 100 person-years), who are not at increased risk of bleeding.

“We recommend that aspirin use in the primary prevention of acute myocardial infarction and other atherothrombotic cardiovascular events in subjects of both sexes is guided by an assessment of the underlying cardiovascular risk,” the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)